Initially focused on launching our PICC device, the HydroPICC™, we are also in the early stages of development of hemodialysis and implantable port devices.
The HydroPICC is designed to greatly reduce the need for further modification with additives or coatings to achieve its anti-thrombogenic properties. Our technology is less likely to be recognized by the body as a foreign material and therefore reduces the chance that it will trigger the body’s thrombotic response, the initial trigger to a cascade of events that leads to catheter occlusion and bacterial colonization. The net result will be improved procedural efficiencies, a higher quality of care and improved reimbursement.
Efficacy: Access Vascular has completed benchtop biocompatibility and preclinical studies (where the catheter is indwelling in various animal models), and the material has proven to reduce thrombogenicity. Our testing has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies.
Regulatory Path: We anticipate a successful 510(k) submission and path to commercialization.
Tested for 120 minutes
We will submit a 510(k) application for the HydroPICC in late 2017, and anticipate commercialization launch in early 2018.